Overcoming challenges in Type 2 diabetes management to improve patient outcomes

References

• American Diabetes Association. Total Prevalence of Diabetes and Pre-Diabetes. American Diabetes Association, VA, USA (2009).
   Google Scholar
• US Department of Health and Human Services. National Diabetes Statistics, 2007. National Diabetes Information Clearinghouse, MD, USA, NIH Publication No. 08–3892 (2008).
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care.33(Suppl. 1), S11–S61 (2010).
   PubMed Web of Science ®Google Scholar
• Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat. Report8(8), 1–29 (2008).
   PubMedGoogle Scholar
• Katragadda S, Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am. J. Ther.17, e11–e23 (2010).
   PubMedGoogle Scholar
• Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann. Intern. Med.144(7), 465–474 (2006).
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med.353(5), 487–497 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes. Metab.11(6), 527–533 (2009).
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am. J. Manag. Care14(2), 71–75 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed.79(3), 184–191 (2008).
   PubMedGoogle Scholar
• Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes (8th Edition). Professional Communications, Inc., NY, USA 1–192 (2007).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care32(1), 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Grant R, Adams AS, Trinacty CM et al. Relationship between patient medication adherence and subsequent clinical inertia in Type 2 diabetes glycemic management. Diabetes Care30(4), 807–812 (2007).
   PubMed Web of Science ®Google Scholar
• Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care33(3), 501–506 (2010).
   PubMed Web of Science ®Google Scholar
• Rodondi N, Peng T, Karter AJ et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann. Intern. Med.144(7), 475–484 (2006).
   Google Scholar
• Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in Type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res. Clin. Pract.77(2), 280–285 (2007).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract.15(6), 541–559 (2009).
   Web of Science ®Google Scholar
• De Ferrari GM, Klersy C, Ferrero P et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur. J. Heart Fail.9(5), 502–509 (2007).
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL-cholesterol in patients with Type 2 diabetes inadequately controlled on sulfonylurea-based therapy. Diabetes Care31(8), 1479–1484 (2008).
   PubMed Web of Science ®Google Scholar
• Komajda M, McMurray JJ, Beck-Nielsen H et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur. Heart J.31(7), 824–831 (2010).
   PubMed Web of Science ®Google Scholar
• Olansky L. Do incretin-based therapies cause acute pancreatitis? J. Diabetes Sci. Technol.4(1), 228–229 (2010).
   PubMedGoogle Scholar
• Kirby M, Yu DM, O’Connor S, Gorrell M. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. (Lond.)118(1), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in Type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care31(5), 845–851 (2008).
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. JAMA298(2), 194–206 (2007).
   PubMed Web of Science ®Google Scholar
• Green DE. New therapies for diabetes. Clin. Cornerstone8(2), 58–63 (2007).
   Google Scholar
• Glucotrol [package insert]. Pfizer Inc., NY, USA (2009).
   Google Scholar
• Victoza [package insert]. Novo Nordisk A/S, NJ, USA (2010).
   Google Scholar
• Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med.121(2), 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• Product Monograph: Glucophage® Metformin Hydrochloride. Manufacturer’s standard 500 mg and 850 mg tablets. Oral Antihyperglycemic Agent (Version 4.0). sanofi-aventis Canada Inc. Submission Control No.: 128147. Revised 29 October (2009).
   Google Scholar
• Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (1), CD002967 (2006).
   Google Scholar
• Glucophage [package insert]. Bristol-Myers Squibb Co., NJ, USA (2008).
   Google Scholar
• Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with Type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ3(39), b4731 (2009).
   Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA299(13), 1561–1573 (2008).
   PubMed Web of Science ®Google Scholar
• Tenzer-Iglesias P, Brunton S. Managing postprandial glucose levels in patients with diabetes. J. Fam. Pract.57(1 Suppl.), S17–S24 (2008).
   Google Scholar
• Dagenais GR, Gerstein HC, Holman R et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care31(5), 1007–1014 (2008).
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes54(4), 1150–1156 (2005).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. ACTos NOW for the prevention of diabetes (ACT NOW) study. Late-breaking oral presentation at: 68th Scientific Sessions of the American Diabetes Association. CA, USA 6–10 June 2008.
   Google Scholar
• Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA296(21), 2572–2581 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Actos [package insert]. Takeda Pharmaceuticals America Inc., IL, USA (2008).
   Google Scholar
• Avandia [package insert]. GlaxoSmithKline, NC, USA (2009).
   Google Scholar
• Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in Type 2 diabetes. Diabetes Metab.34(Suppl. 2), S65–S72 (2008).
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with Type 2 diabetes mellitus. Pharmacotherapy29(12 Pt 2), 55S–67S (2009).
   PubMed Web of Science ®Google Scholar
• Verspohl EJ. Novel therapeutics for Type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase inhibitors. Pharmacol. Ther.124(1), 113–138 (2009).
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin.24(1), 275–286 (2008).
   PubMed Web of Science ®Google Scholar
• Byetta [package insert]. Amylin Pharmaceuticals, Inc, CA, USA (2009).
   Google Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of Type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care30(6), 1335–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem.48(15), 5025–5037 (2005).
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of Type 2 diabetes. Drugs Today (Barc.).43(11), 801–814 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E et al. Effect of saxagliptin monotherapy in treatment-naive patients with Type 2 diabetes. Curr. Med. Res. Opin25(10), 2401–2411 (2009).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa M, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes on metformin alone. Diabetes Care32(9), 1649–1655 (2009).
   PubMed Web of Science ®Google Scholar
• Pfützner A, Paz-Pacheco E, Berglind N et al. Saxagliptin initial combination with metformin provides sustained glycemic control and is well tolerated in patients with Type 2 diabetes: 76-week results. Diabetes59(Suppl. 1), A17 (2010) (Abstract 64-OR).
   Google Scholar
• Ravichandran S, DeFronzo R, Garber AJ et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetologia52(Suppl. 1), S60 (2009) (Abstract 132).
   Google Scholar
• Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with Type 2 diabetes inadequately controlled on metformin: a 2-year study. Int. J. Clin. Pract.64(5), 562–576 (2010).
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with Type 2 diabetes. Diabetes Obes. Metab.12(5), 442–451 (2010).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab.87(3), 1239–1246 (2002).
   PubMed Web of Science ®Google Scholar
• Buteau J. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Metab.34(Suppl. 2), S73–S77 (2008).
   PubMed Web of Science ®Google Scholar
• Khoo J, Rayner CK, Jones KL, Horowitz M. Incretin-based therapies: new treatments for Type 2 diabetes in the new millennium. Ther. Clin. Risk Manag.5(3), 683–698 (2009).
   PubMedGoogle Scholar
• Apidra [package insert]. Sanofi-Aventis US LLC, NJ, USA (2009).
   Google Scholar
• NovoLog [package insert]. Novo Nordisk A/S, NJ, USA (2002–2009).
   Google Scholar
• Levemir [package insert]. Novo Nordisk A/S, NJ, USA (2005–2009).
   Google Scholar
• Lantus [package insert]. Sanofi-Aventis US LLC, NJ, USA (2007).
   Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for Type 2 diabetes mellitus. Cochrane Database Syst. Rev.2, CD005613 (2007).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care28(5), 1092–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet.352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Zoungas S, De Galan BE, Ninomiya T et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with Type 2 diabetes. Diabetes Care32(11), 2068–2074 (2009).
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358(6), 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfützner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab.11(6), 611–622 (2009).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract.63(1), 46–55 (2009).
   PubMed Web of Science ®Google Scholar
• Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with Type 2 diabetes: a randomised controlled trial. Int. J. Clin. Pract.63(9), 1395–1406 (2009).
   PubMed Web of Science ®Google Scholar
• Hollander P, Li J, Allen E, Chen R; for the CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with Type 2 diabetes and inadequate control on thiazolidinedione alone. J. Clin. Endocrinol. Metab.94(12), 4810–4819 (2009).
   PubMed Web of Science ®Google Scholar
• Qi DS, Teng R, Jiang M. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with Type 2 diabetes. Presented at: 44th Annual Meeting of the European Association for the Study of Diabetes. Rome, Italy, 7–11 September 2008.
   Google Scholar
• DeFronzo R, Hissa MN, Garber AJ et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with Type 2 diabetes. Diabetes58(Suppl. 1), 547-P (2009).
   Google Scholar